Inhibikase Therapeutics, Inc.
IKT
$2.38
$0.020.85%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -68.39% | 38.03% | 110.93% | 424.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -68.39% | 38.03% | 110.93% | 424.43% |
| Cost of Revenue | -4.75% | -10.20% | 13.84% | 13.16% | 10.50% |
| Gross Profit | 2.44% | 9.09% | -13.55% | -12.14% | -8.42% |
| SG&A Expenses | 5.52% | 6.64% | 5.64% | 8.28% | 2.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.38% | -4.66% | 10.95% | 11.50% | 7.66% |
| Operating Income | -0.21% | 3.85% | -10.74% | -10.82% | -6.30% |
| Income Before Tax | -2.27% | 3.40% | -7.32% | -5.40% | -1.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.27% | 3.40% | -7.32% | -5.40% | -1.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.27% | 3.40% | -7.32% | -5.40% | -1.67% |
| EBIT | -0.21% | 3.85% | -10.74% | -10.82% | -6.30% |
| EBITDA | -0.97% | 3.15% | -47.42% | -125.19% | -339.79% |
| EPS Basic | 25.92% | 29.44% | 25.44% | 21.99% | 17.75% |
| Normalized Basic EPS | 25.92% | 29.45% | 25.45% | 21.99% | 17.75% |
| EPS Diluted | 25.92% | 29.44% | 25.44% | 21.99% | 17.75% |
| Normalized Diluted EPS | 25.92% | 29.45% | 25.45% | 21.99% | 17.75% |
| Average Basic Shares Outstanding | 36.80% | 36.44% | 43.81% | 36.68% | 25.38% |
| Average Diluted Shares Outstanding | 36.80% | 36.44% | 43.81% | 36.68% | 25.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
